Prescient Therapeutics Limited (ASX:PTX)

Prescient Therapeutics Revenue

In the fiscal year ending June 30, 2026, Prescient Therapeutics had annual revenue of 3.45M AUD, down -20.78%. Prescient Therapeutics had revenue of 2.29M in the half year ending June 30, 2026, with 29.38% growth. That makes Prescient Therapeutics the 41,975th largest company in the world by revenue and 852nd in Australia.

• Revenue: 3.45M
• Revenue Growth: -20.78%
• P/S Ratio: 18.89
• Revenue / Employee: 1.15M
• Employees: 3
• Market Cap: 67.49M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	3.45M	-905.30K	-20.78%
Jun 30, 2025	4.36M	644.03K	17.35%
Jun 30, 2024	3.71M	1.28M	52.89%
Jun 30, 2023	2.43M	538.79K	28.52%
Jun 30, 2022	1.89M	703.86K	59.37%

Data Source: S&P Global Market Intelligence Last updated: Aug 20, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 20, 2026

Data Sources Report a data error